Cancer pain remains undertreated and a significant number of patients with cancer pain die from severe untreated pain. With increasing survival rate in cancer, the prevalence of cancer pain is also increasing in number. Though majority of patients with cancer pain can be effectively treated with conventional medical management, still a significant portion of patients required some form of interventional pain management techniques. Among the interventional techniques, intrathecal drug delivery is increasingly used in cancer pain management. Our objective of this article is to review literatures and clinical studies on intrathecal drug delivery system (IDDS) in cancer pain management and to provide updates on its use, precautions, contraindications, side effects and its management, socioeconomic consideration, and management of IDDS in difficult or uncommon situations.
WeinsteinSMAndersonPRYaskoAWDriverL. Pain management. In: PazdurRCoiaLRHoskinsWJWagmanLD, eds. Cancer Management: A Multidisciplinary Approach. 5th ed. Melville, NY: PRR; 2001:715–737.
2.
LordonSP. Interventional approach to cancer pain. Curr Pain Headache Rep. 2002;6(3):202–206.
3.
BhatnagarS. (editorial). Interventional pain management: need of the hour for cancer pain patients. Indian J Palliat Care. 2009;15(2):93–94.
4.
FoleyKM. Acute and chronic cancer pain syndromes. In: DoyleDHanksGChernyNCalmanK, eds. Oxford Textbook of Palliative Medicine. 3rd ed. Oxford University Press, Oxford, New York; 2004:298–316.
5.
van den Beuken-van EverdingenMHde RijkeJMKesselsAGSchoutenHCvan KleefMPatijnJ. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18(9):1437–1449.
6.
American Cancer Society. Cancer Facts & Figures2011. Atlanta, GA: American Cancer Society; 2011.
7.
ZechDFJGrondSLycnJHertelDLehmannKA. Validation of the world health organisation guidelines for cancer pain relief: a 10 year prospective study. Pain. 1995;63(1):65–76.
8.
VentafriddaVTamburiniMCaraceniADeConnoFNaldiF. A validation study of the WHO method for cancer pain relief. Cancer. 1987;59(4):850–856.
9.
SloanPAMelzackR. Long-term patterns of morphine dosage and pain intensity among cancer patients. Hosp J. 1999;14(2):35–47.
10.
DeerTRSmithHSBurtonAW. Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain. Pain Physician. 2011;14(3):E283–E312.
11.
WangJKNauss LeeAThomasJE. Pain relief by intrathecally applied morphine in man. Anesthesiology. 1979;50(2):149–151.
12.
OnofrioBMYakshTLArnoldPG. Continuous low dose intrathecal morphine administration in the treatment of chronic pain of malignant origin. Mayo Clin Proc. 1981;56(8):516–520.
13.
CoombsDWMaurerLHSaundersRLGaylorM. Outcomes and complications of continuous intraspinal narcotic analgesia for cancer pain control. J Clin Oncol. 1984;2(12):1414–1420.
14.
kramesESGershowJGlassbergA. Continuous infusion of spinally administered narcotics for the relief of pain due to malignant disorders. Cancer. 1985;56(3):696–702.
15.
OnofrioBMYakshTL. Long-term pain relief produced by intrathecal morphine infusion in 53 patients. J Neurosurg. 1990;72(2):200–209.
16.
FollettKAHitchonPWPiperJKumarVClamnGJonesMP. Response of intractable pain to continuous intrathecal morphine: a retrospective study. Pain. 1992;49(1):2–5.
17.
SoniBMManiRMOoTVaidyanathanS. Treatment of spasticity in a spinal cord-injured patient with intrathecal morphine due to intrathecal baclofen tolerance—a case report and review of literature. Spinal Cord. 2003;41(10):586–589.
18.
BurtonAWRajagopalAShahHN. Epidural and intrathecal analgesia is effective in treating refractory cancer pain. Pain Med. 2004;5(3):239–247.
19.
DeerTKramesESHassenbuschSJ. Polyanalgesic consensus conference 2007: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation. 2007;10:300–328.
20.
Ballantyne JC, Carwood CM. Comparative efficacy of epidural, subarachnoid and intracerebroventricular opioids in patients with pain due to cancer. Cochrane Database Syst Rev. 2005;25(1):art no. CD 005178.
21.
SmithTJStaatsPSDeerT. Implantable Drug Delivery Systems Study Group. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity and survival. J Clin Oncol. 2002;20(19):4040–4049.
22.
DeerTWinkelmullerWErdineSBedderMBurchielK. Intrathecal therapy for cancer and nonmalignant pain: patient selection and patient management. Neuromodulation. 1999;2(2):55–66.
23.
PatelVBManchikantiLSinghVSchultzDMHayekSMSmithHS. Systematic review of intrathecal infusion systems for long-term management of chronic noncancer pain. Pain Physician. 2009;12(2):345–360.
24.
RaffaeliWSartiDDemartiniLSotgiuABonezziC; Italian Ziconotide Group. Italian registry on long-term intrathecal ziconotide treatment. Pain Physician. 2011;14(1):15–24.
25.
World Health Organization. Cancer Pain Relief. Second Edition. With a Guide to Opioid Availability. WHO, Geneva, Switzerland: WHO publication; 1996:36–37.
26.
MeuserTPietruckCRadbruchLStutePLehmannKAGrondS. Symptoms during cancer pain treatment following WHO guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain. 2001;93(3):247–257.
27.
ZechDFGrondSLynchJHertelDLehmannKA. Validation of world health organization guidelines for cancer pain relief: a 10-year prospective study. Pain. 1995;63(1):65–76.
28.
OnofrioBMYakshTL. Long-term pain relief produced by intrathecal morphine infusion in 53 patients. J Neurosurg. 1990;72(2):200–209.
29.
OnofrioBMYakshTLArnoldPG. Continuous low-dose intrathecal morphine administration in the treatment of chronic pain of malignant origin. Mayo Clin Proc. 1981;56(8):516–520.
30.
YakshTLReddySV. Studies in the primate on the analgetic effects associated with intrathecal actions of opiates, alpha-adrenergic agonists and baclofen. Anesthesiology. 1981;54(6):451–467.
DeerTRKramesELevyRMHassenbuschSJPragerJP. Practice choices and challenges in the current intrathecal therapy environment: an online survey. Pain Med. 2009;10(2):304–309.
33.
KramesESOlsonK. Clinical realities and economic considerations: patient selection in intrathecal therapy. J Pain Symptom Manage. 1997;14(3 suppl):S3–S13.
34.
Physicians’ Desk Reference. 62nd ed. Montvale, NJ: Thomson PDR; 2008:1198.
35.
ZazaCBaineN. Cancer pain and psychosocial factors: a critical review of the literature. J Pain Symptom Manage. 2002 Nov; 24(5):526–542.
36.
SteinmanRH. The cancer patient with anxiety and chronic pain. Pain. Clinical Updates. 2009;27:1–5.
37.
MonroeB. Psychological evaluation of patient and family. In: SykesNFallonMTPattRB, ed. Clinical pain management: cancer pain, New York: Oxford University Press; 2003:73–85.
38.
WardSEGoldbergNMiller-McCauleyV. Patient-related barriers to management of cancer pain. Pain. 1993;52(3):319–324.
39.
WardSECarlson-DakesKHughesSHKwekkeboomKLDonovanHS. The impact of quality of life on patient-related barriers to pain management. Res Nurs Health. 1998;21(5):5–13.
40.
AbernethyAPWheelerJLFortnerBV. A health economic model of breakthrough pain. Am J Manag Care. 2008;14(5 suppl 1):S129–S140.
41.
Mueller-SchwefeGHassenbuschSJReigE. Cost effectiveness of intrathecal therapy for pain. Neuromodulation. 1999;2(2):77–87.
42.
SouthallJLBeddallCRaphaelJH. Cost utility analysis of intrathecal pump implant for chronic nonmalignant low back pain. Neuromodulation. 2006;9(2):156–157.
43.
DeerTRansonMStewartD. Relevant anatomy for spinal delivery. In: KramesEHunter PeckhamPRezaiA. eds. Neuromodulation. New York, NY: Elsevier, New York; 2009.
44.
KnightKHBrandFMMchaourabASVenezianoG. Implantable intrathecal pumps for chronic pain: Highlights and updates. Croat Med J. 2007;48(1):22–34.
45.
PragerJJacobsM. Evaluation of patients for implantable pain modalities: medical and behavioral assessment. Clin J Pain. 2001;17(3):206–214.
46.
LevyRM. Quantitative, crossover, doubleblind trial paradigm for patient screening for chronic intraspinal narcotic administration. Neurosurg Focus. 1997;2(1):e2.
47.
RosenstielAKKeefeFJ. The use of coping strategies in chronic low back pain patients: relationship to patient characteristics and current adjustment. Pain. 1983;17(1):33–44.
48.
StearnsLBoortz-MarxRDu PenS. Intrathecal drug delivery for the management of cancer pain a multidisciplinary consensus of best clinical practices. J Support Oncol. 2005;3(6):399–408.
49.
BedderMDBurchielKLarsonA. Cost analysis of two implantable narcotic delivery systems. J Pain Symptom Manage. 1991;6(6):368–373.
MercadanteS. Problems of long-term spinal opioid treatment in advanced cancer patients. Pain. 1999;79(1):1–13.
52.
Intrathecal drug delivery for the management of pain and spasticity in adults; recommendations for best clinical practice. The British Pain Society 2008. www.britishpainsociety.org, last assess July 7th 2011.
53.
IliasWIe PolainBBuchserEDemartiniL, oPTiMa study group. Patient-controlled analgesia in chronic pain patients: experience with a new device designed to be used with implanted programmable pumps. Pain Pract. 2008;8(3):164–170.
54.
KrakovskyAA. Complications associated with intrathecal pump drug delivery. A retrospective evaluation. AJPM. 2007;17(1):4–10.
55.
PaiceJAPennRDShottS. Intraspinal morphine for chronic pain: a retrospective, multicenter study. J Pain Symptom Manage. 1996:11(2):71–80.
56.
TurnbullDKShepherdDB. Post dural puncture headache: pathogenesis, prevention and treatment. Br J Anaesth. 2003;91(5):718–729.
57.
SinghPKJainRMishraSKumarSBhatnagarSDeoS. Management of pericatheter cerebrospinal fluid leak after intrathecal implantation of a drug delivery system. Am J Hosp Palliat Care. 2008;25(3):237–239.
58.
CarrDBCousinsMJ. Spinal route of analgesia: opioids and future options for spinal analgesic chemotherapy. In: CousinsMJCarrDBHorlockerTTBridenbaughPO, eds. Neural Blockade in Clinical Anesthesia and Pain Medicine. 4th ed. Philadelphia, Pennsylvania: Wolters Kluwer Lippincott Williams & Wilkins; 2008:886–947.
59.
NorthRBCutchisPNEpsteinJALongDM. Spinal cord compression complicating subarachnoid infusion of morphine: case report and laboratory experience. Neurosurgery. 1991;29(5):778–784.
60.
CoffeyRJBurchielK. Inflammatory mass lesions associated with intrathecal drug infusion catheters: report and observations on 41 patients. Neurosurgery. 2002;50(1):78–87.
61.
YakshTLHassenbuschSBurchielKHildebrandKRPageLMCoffeyRJ. Inflammatory masses associated with intrathecal drug infusion: a review of preclinical evidence and human data. Pain Med. 2002;3(4):299–312.
ToombsJDFollettKARosenquistRWBentonLM. Intrathecal catheter tip inflammatory mass: a failure of clonidine to protect. Anesthesiology. 2005;102(3):687–690.
65.
MieleVJPriceKOBloomfieldSHoggJBailesJE. A review of intrathecal morphine therapy related granulomas. Eur J Pain. 2006;10(3):251–261.
66.
LangsamA. A case of spinal cord compression syndrome by a finrotic mass presenting in a patients with intrathecal pain management pump system. J Pain. 1999;83(1):97–99.
AbsRVerhelstJMaeyaertJ. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab. 2000;85(6):2215–2222.
69.
AndersonVCBurchielKJ. A prospective study of long-term Intrathecal morphine in the management of chronic nonmalignant pain. Neurosurgery. 1999;44(2):289–300.
70.
GregoryMABrock-UtneJGBuxSDowningJW. Morphine concentration in the brain and spinal cord after subarachnoid morphine injection in baboons. Anesthesia Analg. 1985;64(9):929–932.
71.
DahmPNitescuPAppelgrenLCurelaruI. Continuous intrathecal infusion of opioid and bupivacaine in the treatment of refractory pain due to postherpetic neuralgia: a case report. Neuromodulation. 1998;1(2):85–89.
72.
KramesESLanningRM. Intrathecal infusional analgesia for nonmalignant pain: analgesic efficacy of intrathecal opioid with or without bupivacaine. J Pain Symptom Manage. 1993;8(8):539–548.
73.
van DongenRTCrulBJvan EgmondJ. Intrathecal coadministration of bupivacaine diminishes morphine dose progression during long-term intrathecal infusion in cancer patients. Clin J Pain. 1999;15(3):166–172.
74.
SjobergMNitescuPAppelgrenLCurelaruI. Long-term intrathecal morphine and bupivacaine in patients with refractory cancer pain. Results from a morphine: bupivacaine dose regimen of 0.5:4.75 mg/ml. Anesthesiology. 1994;80(2):284–297.
75.
AkermanBArwestromEPostC. Local anesthetics potentiate spinal morphine antinociception. Anesth Analg. 1988;67(10):943–948.
76.
CoombsDWSaundersRLLachanceDSavageSRagnarssonTSJensenLE. Intrathecal morphine tolerance: use of intrathecal Clonidine, DADLE, and intraventricular morphine. Anesthesiology. 1985;62(3):358–363.
77.
CoombsDWSaundersRLFratkinJDJensonLEMurphyCA. Continuous intrathecal hydromorphone and Clonidine for intractable cancer pain. J Neurosurg. 1986;64(6):89–894.
78.
SiddallPJGrayMTurowskiSCousinsMJ. Intrathecal morphine and Clonidine in the management of spinal cord injury pain: a case report. Pain. 1994;59(1):147–148.
79.
BowersoxSSGadboisTSinghTPettusMWangYXLutherRR. Selective N-type neuronal voltage-sensitive calcium channel blocker, SNX-111, produces spinal antinociception in rat models of acute, persistent, and neuropathic pain. J Pharmacol Exp Ther. 1996;279(3):1234–1249.
80.
RauckRLWallaceMSLeongMS. A randomised, double blind, placebo controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage. 2006;31(5):393–406.
81.
ShieldsDMontenegroRAclanJ, Chemical stability of admixtures combining ziconotide with baclofen during simulated intrathecal administration. Neuromodulation. 2007;10(suppl 1):112–172.
82.
ShieldsDMontenegroR, Chemical stability of ziconotide-clonidine hydrochloride admixtures with and without morphine sulfate during simulated intrathecal administration. Neuromodulation. 2007;10(suppl 1):6–11.
83.
HildebrandKRElsberryDEDeerTR. Stability, compatibility, and safety of intrathecal bupivacaine administered via an implantable delivery system. Clin J Pain. 2001;17(3):239–244.
84.
HildebrandKRElsberryDEAndersonVC. Stability and compatibility of hydromorphone in an implantable infusion system. J Pain Symptom Manage. 2001;22(6):1045–1047.
85.
RudichZPengPDunnEMcCarthyC. Stability of clonidine in clonidine hydromorphone mixture from implanted intrathecal infusion pumps in chronic pain patients. J Pain Symptom Manage. 2004;28(6):599–602.
86.
ClassenAMWimbishGHKupiecTC. Stability of admixture containing morphine sulfate, buvicaine hydrochloride, and clonidine hydrochloride in an implantable infusion system. J Pain Symptom Manage. 2004;28(6):603–606.
87.
WulfHGleimMMignatC. The stability of mixtures of morphine hydrochloride, bupivicaine hydrochloride and clonidine hydrochloride in portable pump reservoirs for the management of chronic pain syndromes. J Pain Symptom Manage. 1994;9(5):308–311.
88.
ThomasJ.SmithMDPatrickJ. Coyne. How to use implantable intrathecal drug delivery systems for refractory cancer pain. J Support Oncol. 2003;1(1):73–76.
89.
RozziniRFrisoniGBFerrucciL. Geriatric index of comorbidity: validation and comparison with other measures of comorbidity. Age Ageing. 2002;31(4):277–285.
